rhPDGF-BB (Augment) is a safe alternative to autologous graft in foot and ankle fusion .
Prospective, Randomized, Multi-Center Feasibility Trial of rhPDGF-BB Versus Autologous Bone Graft in a Foot and Ankle Fusion Model
Foot Ankle Int. 2011 Apr;32(4):344-54.20 patients requiring hindfoot fusion were randomized to receive either a biosynthetic bone graft substitute (Augment Bone Graft, a recombinant form of platelet-derived growth factor (rhPDGF-BB)) or an autologous bone graft (ABG), in order to compare safety and efficacy between the two graft types. The results of this study suggest the biosynthetic bone graft is a safe and efficacious alternative to ABG, which could provide improved outcomes for future patients undergoing procedures requiring bone grafts if this treatment option is incorporated in to common practice.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
